Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids

被引:6
|
作者
Baakhtari, Sadaf Asl [1 ]
McCombie, Andrew [2 ]
Huinink, Sebastiaan ten Bokkel [1 ,5 ]
Irving, Peter [7 ]
Siegel, Corey A. [8 ]
Mulder, Roger [3 ]
Mulder, Chris J. [5 ,6 ]
Gearry, Richard [1 ,4 ]
机构
[1] Univ Otago, Dept Med, Christchurch, New Zealand
[2] Christchurch Hosp, Dept Surg, POB 4345, Christchurch, New Zealand
[3] Christchurch Hosp, Dept Psychol Med, Christchurch, New Zealand
[4] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
[5] Vrije Univ Amsterdam Med Ctr, Dept Med, Amsterdam, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
[7] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London, England
[8] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03766 USA
关键词
Corticosteroids; Side effects; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; CROHNS-DISEASE; NATURAL-HISTORY; THERAPY; ARTICLE; INDEX;
D O I
10.1159/000478772
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: We aimed to investigate the factors that make inflammatory bowel disease (IBD) patients more or less likely to be willing to take corticosteroids. Methods: Respondents completed a questionnaire. The primary outcome was whether the respondents would or would not use corticosteroids again to treat their IBD. Three separate univariate and multivariate analyses were performed to examine which variables predicted willingness to take steroids, including specific side effects. Results: Four hundred fifty three respondents (321 with Crohn's disease, 115 with ulcerative colitis; mean age 40 years, 297 [66%] female) completed the questionnaire. Corticosteroid efficacy (OR 6.83, 95% CI 3.67-12.7), lack of previous negative side effects (OR 0.11, 95% CI 0.04-0.32), and positive side effects (OR 2.96, 95% CI 1.63-5.40) were associated with a willingness to use corticosteroids in the future. In multivariate analysis, weight gain (OR 0.53, 95% CI 0.29-0.98) and hallucinations (OR 0.28, CI 0.09-0.89) were associated with an unwillingness to use corticosteroids again, whereas increased energy (OR 2.30, 95% CI 1.20-4.42) was the only significant positive side effect in a multivariate model. Conclusions: Past experiences with corticosteroids influence whether patients will take corticosteroids again. Clinicians should enquire about side effects and positive psychological symptoms associated with corticosteroid use. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:33 / 39
页数:7
相关论文
共 50 条
  • [1] Corticosteroids in Inflammatory Bowel Disease Patients: A Practical Guide for Physicians
    Di Paolo, Maria Carla
    Pagnini, Cristiano
    Graziani, Maria Giovanna
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2021, 16 (03) : 210 - 218
  • [2] Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease
    Gionchetti, Paolo
    Rizzello, Fernando
    Annese, Vito
    Armuzzi, Alessandro
    Biancone, Livia
    Castiglione, Fabiana
    Comberlato, Michele
    Cottone, Mario
    Danese, Silvio
    Daperno, Marco
    D'Inca, Renata
    Fries, Walter
    Kohn, Anna
    Orlando, Ambrogio
    Papi, Claudio
    Vecchi, Maurizio
    Ardizzone, Sandro
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 604 - 617
  • [3] Prescribed cumulative dosage of corticosteroids to patients with inflammatory bowel disease diagnosed between 2006 and 2020: a retrospective observational study
    Iiristo, Johannes
    Karling, Pontus
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [4] The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
    Dorrington, Alexander M.
    Selinger, Christian P.
    Parkes, Gareth C.
    Smith, Melissa
    Pollok, Richard C.
    Raine, Tim
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (09) : 1316 - 1329
  • [5] Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids
    Weber, Nicholas K.
    Bruining, David H.
    Loftus, Edward V., Jr.
    Tremaine, William J.
    Augustin, Jessica J.
    Becker, Brenda D.
    Kammer, Patricia P.
    Harmsen, William Scott
    Zinsmeister, Alan R.
    Pardi, Darrell S.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) : 2644 - 2651
  • [6] Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study
    Oxelmark, Lena
    Lindberg, Annelie
    Lofberg, Robert
    Sternby, Berit
    Eriksson, Anders
    Almer, Sven
    Befrits, Ragnar
    Fossum, Bjoorn
    Karlen, Per
    Brostrom, Olle
    Tysk, Curt
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 28 (11) : 1320 - 1328
  • [7] Patients' perspectives on marijuana use for inflammatory bowel disease: a multicenter survey
    El-Dallal, Mohammed
    Anderson, Kelsey L.
    Saroufim, Ariana
    Wang, Linda F.
    Systrom, Hannah K.
    Hoque, Asahi
    Pasam, Ravi Teja
    Osman, Karim Tarek
    Chaudrey, Khadija
    Feuerstein, Joseph D.
    ANNALS OF GASTROENTEROLOGY, 2023, 36 (06): : 624 - 629
  • [8] An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease
    Berrill, J. W.
    Gallacher, J.
    Hood, K.
    Green, J. T.
    Matthews, S. B.
    Campbell, A. K.
    Smith, A.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 25 (11) : 918 - E704
  • [9] Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease
    Afzali, Anita
    Park, Christopher J.
    Zhu, Kehao
    Hu, Jie Kate
    Sharma, Prachi
    Sinanan, Mika N.
    Lee, Scott D.
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) : 1887 - 1895
  • [10] The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study
    Gensmyr-Singer, Helena
    Werner, Marten
    Karling, Pontus
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17